Pharmacy Times

JUNE 27, 2025

Treatment-related adverse events (AEs) included nausea (77.8% vs 10.8%, respectively), and major bleeding events (2.4% 5 Primary end points included safety, with secondary end points of overall response rate (ORR), progression-free survival (PFS), and duration of response. ORRs were 94.4% in the TN cohort (95% CI, 72.7%-99.9%)

Pharmacy Technician

Pharmacy Times

JULY 21, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 24, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JULY 26, 2025

Although some of these medications have additional FDA-approved uses (ie, rivaroxaban to reduce the risk of thrombotic vascular events in patients with peripheral artery disease), all 4 DOACs are approved for the treatment and prevention of venous thromboembolism and stroke prevention in nonvalvular atrial fibrillation (AFib).

Pharmacy Technician

Pharmacy Times

JULY 21, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 9, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JULY 12, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 12, 2025

About the 2025 OPC Meeting At this year’s OPC meeting, attendees will have the opportunity to showcase clinical research and practice management insights or explore the latest advancements in oncology pharmacy during the poster session and networking reception.

Pharmacy Technician

Pharmacy Times

JUNE 19, 2025

Nacher : I think, as I said, rusfertide being a first-in-class hepcidin mimetic is huge—especially for patients with [PV]—to hopefully reduce the phlebotomy burden and prevent some of the sequelae of the disease, including cardiovascular and thrombotic events.

Pharmacy Technician

Pharmacy Times

JUNE 18, 2025

2 More recent changes in many states include the ability to prescribe oral contraceptives and plan outreach events to monitor blood pressure or cholesterol; the latter, when coupled with referral to appropriate medical services, is a valuable intervention. 2 The pharmacy profession needs to improve in 2 areas.

Pharmacy Technician

Pharmacy Times

JUNE 16, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 11, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 4, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmaceutical Manufacturing

Pharmacy Times

JULY 18, 2025

Community take-backs: Community groups may sponsor medication takeback events as well; however, they are typically short-term and must have a law enforcement officer in attendance. The patient can obtain a prepaid mailback envelope, fill it according to the directions, seal it, and mail it to the indicated location.

HIV Treatment and Prevention Agents

Pharmacy Times

JUNE 13, 2025

However, in areas that only have 1 pharmacy location and no existing primary care providers, and therefore, no existing relationship, patients may not be able to receive care in the event of certain illnesses (eg, influenza, strep throat). This is where collaborative practice agreements (CPAs) come in.

Pharmacy Technician

Pharmacy Times

JUNE 25, 2025

Despite its proven efficacy, the conventional oral administration of lenalidomide presents challenges due to its short half-life and the high systemic exposure required to sustain therapeutic drug levels, which can lead to significant toxicities, particularly grade 3 or 4 hematologic adverse events (AEs).

Pharmacy Technician

Pharmacy Times

JULY 24, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JUNE 23, 2025

By meticulously reviewing medication regimens, reconciling discrepancies, and providing comprehensive education to patients and caregivers, they significantly reduce the likelihood of medication errors and adverse drug events during these vulnerable periods.

Pharmacy Technician

Pharmacy Times

JUNE 25, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JULY 8, 2025

The regimen maintained stem cell collection feasibility with no new safety concerns, despite some adverse events like neutropenia and infections. Five patients died during this time, with causes including disease progression (n = 1), cardiac events (n = 2), and other unrelated causes (n = 2).

Pharmacy Technician

Pharmacy Times

JULY 19, 2025

As a multifactorial condition influenced by both genetic predisposition and lifestyle factors, hypertension is a leading risk factor for serious health outcomes including microvascular complications (retinopathy and nephropathy) and macrovascular events (myocardial infarction and stroke). Serious adverse events occurred in 3.6%

HIV Treatment and Prevention Agents

Pharmacy Times

JUNE 20, 2025

Adverse events were common but comparable between dupilumab and placebo, with no deaths in the dupilumab group. 3 Overall rates of adverse events (AEs) were 96% (n = 51) in the dupilumab arm and 96% (n = 51) in the placebo.

Pharmacy Technician

Pharmacy Times

JULY 16, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JULY 24, 2025

Finerenone, a nonsteroidal MRA, shows promise in reducing HF events and atrial fibrillation, offering potential benefits over steroidal MRAs like spironolactone. Yet, despite growing awareness, HFpEF remains difficult to manage due to nonspecific symptoms, limited clinical trial data, and inconsistencies in diagnosis.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 25, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Vaccines

Pharmacy Times

JUNE 30, 2025

REMS ensured drug safety by requiring certified hospitals to have tocilizumab for severe adverse events management. Increased experience in managing CAR T therapy toxicities has led to the removal of REMS, facilitating broader access. Only some medications—including CAR T therapies—carry REMS designations.

Pharmacy Technician

Pharmacy Times

JULY 22, 2025

Alixorexton was well-tolerated across all doses, with no serious treatment-emergent adverse events, supporting its further study in a global phase 3 trial. 1 Treatment-emergent adverse events (TEAEs) were limited in scope, as alixorexton was safe and tolerated well at all doses in this portion of Vibrance-1.

Pharmacy Technician

Pharmacy Times

JULY 28, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Vaccines

Pharmacy Times

JUNE 9, 2025

The primary end point was mean change in home systolic BP (SBP) from baseline to week 12, and the primary safety outcome was treatment discontinuation due to an adverse event (AE) from baseline to week 12, with secondary end points including differences in clinic and home blood pressure levels and control rates.

Pharmacy Technician

Pharmacy Times

JUNE 20, 2025

Pharmacy Times: What role do you see pharmacists playing in the discussions and advancements presented at the event? There are going to be a lot of key takeaways that will be important for the pharmacist to know. Isaacs: It's great if pharmacists can be there, but even if not, there's a virtual option as well.

Diabetes

Pharmacy Times

JUNE 17, 2025

Medically integrated pharmacy (MIP) interventions using data from a cost avoidance and waste tracker tool show: The net cost avoidance for the MIPs was $6,510,971.28 for the external mail-order pharmacies. Among the 37 practices that reported waste, 768 events were reported, leading to a total drug waste of $11,275,642.16.

Mail-Order Pharmacies

Pharmacy Times

JULY 25, 2025

Additionally, in the event that cultures are obtained, ceftriaxone susceptibilities cannot infer oral cephalosporin susceptibilities. Cultures are not always obtained for CAP; therefore, using oral cephalosporin may be an advantage, as these infections are treated empirically and can cover all the typical respiratory pathogens of concern.

HIV Treatment and Prevention Agents

Pharmacy Times

JUNE 26, 2025

Participants experienced no severe hypoglycemic events, and glycated hemoglobin levels remained below 7%. Most adverse events were mild or moderate, with no serious events linked to zimislecel. Serious adverse events occurred in 6 individuals, leading to extended hospitalization. 1,2 REFERENCES 1.

Diabetes

Pharmacy Times

JUNE 11, 2025

About the 2025 OPC Meeting At this year’s OPC meeting, attendees will have the opportunity to showcase clinical research and practice management insights or explore the latest advancements in oncology pharmacy during the poster session and networking reception.

Pharmacy Technician

Pharmacy Times

JULY 25, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Immunization

Pharmacy Times

JULY 22, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician

Pharmacy Times

JULY 12, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician